|
|
|
| Expression and Clinical Significance of Serum Vasohibin-1 in Type 2 Diabetic Nephropathy |
| PEI Shuang, SU Jianrong |
| Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China |
|
|
|
|
Abstract Objective: To investigate the expression and clinical significance of serum vasohibin-1(VASH-1) in patients with type 2 diabetic nephropathy (DN). Methods: 252 patients with DN were selected as the research group for prospective study. According to the urinary albumin excretion rate (UAER), they were divided into normal albuminuria group (NA group, n=83), microalbuminuria group (MA group, n=85) and large albuminuria group (LA group, n=84). 85 healthy people in the same period were selected as the control group. 24 hours urine was collected for UAER detection, and venous blood was collected for VASH-1, transforming growth factor-β1(TGF-β1), C-reactive protein (CRP),glycosylated hemoglobin(HbA1c) and erythrocyte sedimentation rate(ESR) detection, which were compared among the groups, and the correlation between VASH-1 and other indexes was analyzed. Results: The levels of VASH-1,TGF-β1,UAER,CRP,HbA1c and ESR in the research group were significantly higher than those in the control group. The comparison between the two groups was statistically significant(P<0.05).The levels of research in NA group, MA group and LA group were as follows: LA group> MA group>NA group; the comparison among the three groups was statistically significant(P<0.05).Pearson correlation analysis showed that VASH-1 was positively correlated with TGF-β1, UAER, CRP, HbA1c and ESR (r=0.526, 0.646, 0.529, 0.273, 0.592, P<0.01). Multiple linear regression analysis showed that TGF-β1, UAER, CRP, HbA1c and ESR were independent risk factors for the change of serum VASH-1 level in DN patients. Conclusion: The increased expression of serum VASH-1 in DN patients is closely related to TGF-β1 and inflammatory markers, which provides a new way to study the mechanism of inflammation and fibrosis, to assist diagnosis, to explore therapeutic targets and to develop new drugs in diabetic renal injury.
|
|
|
|
|
|
[1] 曾思皓,周素娴.糖尿病肾病及其氧化应激相关物质研究进展[J].中国医学工程,2020,28(4):37~40.
[2] Tanabe K,Wada J,Sato Y.Targeting angiogenesis and lymphangiogenesis in kidney disease[J].Nat Rev Nephrol,2020,16(5):289~303.
[3] American Diabetes Association.Summary of revisions:standards of medical care in diabetes-2018[J].Diabetes Care,2018,41(Supplement 1):S4~S6.
[4] 桑小溪.糖尿病肾病发病机制的研究进展[J].当代医学,2019,25(17):193~194.
[5] 陈碧霞,张利,吴玲玲,等.糖尿病肾病内皮细胞损伤机制的研究进展[J].解放军医学杂志,2020,45(8):876~883.
[6] Cetin N,Sav NM. Serum vasohibin-1 and suppression of tumorigenicity-2 levels in children with predialysis chronic kidney disease[J].Turk Med Sci,2018,48(3):576~583.
[7] Ren H,Shao Y,Ma X,et al. Expression levels of serum vasohibin-1 and other biomarkers in type 2 diabetes mellitus patients with different urinary albumin to creatinine ratios[J].Diabetes Complications,2019,33(7):477~484.
[8] 高利超,徐兵,刘永安,等.三七皂苷R1抑制TGF-β1/Smad3信号传导对糖尿病肾病大鼠肾脏纤维化和炎症细胞因子的调节作用研究[J].中国免疫学杂志,2020,36(10):1188~1193. |
|
|
|
2021, Vol. 27 
